COCH vs WST vs ATR vs LNTH vs RMD

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). AptarGroup, Inc. (ATR) offers the better valuation at 20. 6x trailing P/E (22. 0x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, AptarGroup, Inc.

(ATR) is the cheapest at 20. 6x versus West Pharmaceutical Services, Inc. at 47. 9x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 17. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 07x versus West Pharmaceutical Services, Inc. 's 4. 57x — a reasonable growth-adjusted valuation.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +338. 1%, compared to -93. 5% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: LNTH returned +42. 9% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 45β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 109% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 56% for AptarGroup, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: ResMed Inc. grew EPS 37. 4% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -92. 4% for COCH. At the gross margin level — before operating expenses — LNTH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 07x versus West Pharmaceutical Services, Inc. 's 4. 57x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Lantheus Holdings, Inc. (LNTH) trades at 17. 7x forward P/E versus 37. 8x for West Pharmaceutical Services, Inc. — 20. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATR: 55. 4% to $188. 00.

In this comparison, COCH (14.

7% yield), ATR (1. 5% yield), RMD (1. 0% yield), WST (0. 3% yield) pay a dividend. LNTH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65), 1. 0% yield, +293. 5% 10Y return). Both have compounded well over 10 years (RMD: +293. 5%, WST: +367. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COCH is a small-cap income-oriented stock; WST is a mid-cap quality compounder stock; ATR is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock. COCH, ATR, RMD pay a dividend while WST, LNTH do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.